Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study

Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce. There is a strong need to accumulate and analyze data on romosozumab treatment for such conditions as osteoporosis. The purpose of this study was to investigate the therapeutic and adverse effects of romosozumab fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayakawa, Tomonori, Suzuki, Takako, Nakano, Masaki, Saito, Makoto, Miyazaki, Akiko, Takahashi, Jun, Nakamura, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085670/
https://www.ncbi.nlm.nih.gov/pubmed/33981812
http://dx.doi.org/10.1016/j.bonr.2021.101068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085670/
https://www.ncbi.nlm.nih.gov/pubmed/33981812
http://dx.doi.org/10.1016/j.bonr.2021.101068

Ejemplares similares